Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Chinese Patent Office
Daiichi Sankyo

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,474,979

« Back to Dashboard

Summary for Patent: 5,474,979

Title: Nonirritating emulsions for sensitive tissue
Abstract:A pharmaceutical composition is disclosed in the form of a nonirritating emulsion which includes at least one cyclosporin in admixture with a higher fatty acid glyceride and polysorbate 80. More particularly, the cyclosporin may be cyclosporin A and the higher fatty acid glyceride may be castor oil. Composition has been found to be of a high comfort level and low irritation potential suitable for delivery of medications to sensitive areas such as ocular tissues. In addition, the composition has stability for up to nine months without crystallization of cyclosporin.
Inventor(s): Ding; Shulin (Irvine, CA), Tien; Walter L. (Irvine, CA), Olejnik; Orest (Trabuco Canyon, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:08/243,279
Patent Claim Types:
see list of patent claims
Composition; Use;

No matches for this query

International Patent Family for Patent: 5,474,979

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark0759773► Subscribe
Germany69529932► Subscribe
Germany69522104► Subscribe
China1198587► Subscribe
China1288722► Subscribe
China1229136► Subscribe
China1152876► Subscribe
Canada2309033► Subscribe
Canada2190485► Subscribe
Denmark1044678► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus